We came across a bullish\u00a0thesis on Merck & Co., Inc. on R. Dennis\u2019s Substack\u2019s Substack by OppCost. In this article, we will summarize the bulls\u2019 thesis on MRK. Merck & Co., Inc.’s share was trading at $106.90 as of January 28th. MRK\u2019s trailing and forward P\/E were 14.28 and 17.27 respectively according to Yahoo Finance.<\/p>\n Copyright: zneb076 \/ 123RF Stock Photo<\/p>\n Merck & Co., Inc. operates as a healthcare company worldwide.\u00a0MRK has emerged as the focus of a high-conviction bullish thesis following the detection of an unusually large institutional options trade on December 8, 2025, when a sophisticated market participant purchased 30,000 April 17, 2026 $110 call contracts, representing roughly $300 million in notional exposure. This trade, executed as MRK retraced precisely to its 21-day exponential moving average, signals a deliberate and well-timed bet on a medium-term repricing rather than a short-term speculative move.<\/p>\n The choice of the April 2026 expiration aligns with multiple anticipated catalysts, including FY2025 earnings, early 2026 pipeline updates, and increasing visibility into Merck\u2019s post-Keytruda growth trajectory. To optimize capital efficiency, the thesis proposes a split-strike risk reversal, selling April $85 puts to finance the $110 calls, anchoring downside risk to the 200-day simple moving average, a level widely viewed as a structural accumulation zone for a high-quality defensive name like Merck.<\/p>\n Fundamentally, confidence is underpinned by the accelerating launch of\u00a0Winrevair, which is already tracking toward blockbuster status, the continued durability and lifecycle extension of the Keytruda franchise, and a deepening pipeline that includes promising assets in cardiology, vaccines, and respiratory disease.<\/p>\n These drivers coincide with a broader macro rotation into healthcare defensives, where Merck trades at a valuation discount while offering a strong dividend yield that reinforces a downside floor. Even absent multiple expansion, the structure offers limited downside with uncapped upside, while a successful fundamental rerating could propel MRK well beyond the $110 strike, delivering an asymmetric and compelling risk\/reward profile.<\/p>\n Previously, we covered a\u00a0bullish thesis<\/b>\u00a0on Merck & Co., Inc. (MRK) by Charly AI in April 2025, which highlighted improving margins, strong free cash flow generation, and durable growth from oncology and cardiovascular franchises. MRK\u2019s stock price has appreciated by approximately 30.50% since our coverage<\/strong> due to earnings momentum and pipeline execution.\u00a0OppCost\u00a0shares a similar view but emphasizes institutional options activity and technical positioning.<\/p>\n<\/p><\/div>\n<\/div>\n<\/div>